PharmaMar’s Lurbinectedin Granted as Orphan drug designation by U.S. FDA for Small Cell Lung Cancer(SCLC)

 PharmaMar’s Lurbinectedin Granted as Orphan drug designation by U.S. FDA for Small Cell Lung Cancer(SCLC)

PharmaMar’s Lurbinectedin Granted as Orphan drug designation by U.S. FDA for Small Cell Lung Cancer(SCLC)

Shots:
  • Lurbinectedin (PM1183) a compound under clinical investigation an inhibitor of RNA polymerase II, essential for transcription process that is over-activated in tumors with transcription addiction
  • The designation may provide certain benefits, with a 7-year market exclusivity if approved leading to an exemption from FDA fees
  •  SCLC is an aggressive cancer ~18% cancer diagnosed with SCLC, with a number of 34,000 new cases in US alone
Click here to read full press release/ article | Ref: US FDA | Image: PRNeewswire

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post